ALNY vs. RPRX, BGNE, HZNP, MYOK, BIIB, BMRN, NBIX, INCY, UTHR, and RGEN
Should you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Royalty Pharma (RPRX), BeiGene (BGNE), Horizon Therapeutics Public (HZNP), MyoKardia (MYOK), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), United Therapeutics (UTHR), and Repligen (RGEN).
Royalty Pharma (NASDAQ:RPRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.
Alnylam Pharmaceuticals received 774 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.81% of users gave Royalty Pharma an outperform vote.
Royalty Pharma has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Royalty Pharma has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Royalty Pharma had 4 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 12 mentions for Royalty Pharma and 8 mentions for Alnylam Pharmaceuticals. Royalty Pharma's average media sentiment score of 1.03 beat Alnylam Pharmaceuticals' score of 0.72 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Royalty Pharma presently has a consensus target price of $43.00, indicating a potential upside of 56.59%. Alnylam Pharmaceuticals has a consensus target price of $216.19, indicating a potential upside of 41.50%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Royalty Pharma is more favorable than Alnylam Pharmaceuticals.
Royalty Pharma has a net margin of 35.70% compared to Royalty Pharma's net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 22.94% beat Royalty Pharma's return on equity.
Summary
Royalty Pharma beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Alnylam Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alnylam Pharmaceuticals Competitors List
Related Companies and Tools
